163 related articles for article (PubMed ID: 37175874)
21. Characterization of the T cell receptor repertoire and melanoma tumor microenvironment upon combined treatment with ipilimumab and hTERT vaccination.
Ellingsen EB; Bounova G; Kerzeli I; Anzar I; Simnica D; Aamdal E; Guren T; Clancy T; Mezheyeuski A; Inderberg EM; Mangsbo SM; Binder M; Hovig E; Gaudernack G
J Transl Med; 2022 Sep; 20(1):419. PubMed ID: 36089578
[TBL] [Abstract][Full Text] [Related]
22. Time to next treatment or death as a candidate surrogate endpoint for overall survival in advanced melanoma patients treated with immune checkpoint inhibitors: an insight from the phase III CheckMate 067 trial.
Branchoux S; Sofeu CL; Gaudin AF; Kurt M; Moshyk A; Italiano A; Bellera C; Rondeau V
ESMO Open; 2022 Feb; 7(1):100340. PubMed ID: 34929616
[TBL] [Abstract][Full Text] [Related]
23. Resolution of tissue signatures of therapy response in patients with recurrent GBM treated with neoadjuvant anti-PD1.
Lu Y; Ng AHC; Chow FE; Everson RG; Helmink BA; Tetzlaff MT; Thakur R; Wargo JA; Cloughesy TF; Prins RM; Heath JR
Nat Commun; 2021 Jun; 12(1):4031. PubMed ID: 34188042
[TBL] [Abstract][Full Text] [Related]
24. Landscape of immune-related signatures induced by targeting of different epigenetic regulators in melanoma: implications for immunotherapy.
Anichini A; Molla A; Nicolini G; Perotti VE; Sgambelluri F; Covre A; Fazio C; Lofiego MF; Di Giacomo AM; Coral S; Manca A; Sini MC; Pisano M; Noviello T; Caruso F; Brich S; Pruneri G; Maurichi A; Santinami M; Ceccarelli M; Palmieri G; Maio M; Mortarini R;
J Exp Clin Cancer Res; 2022 Nov; 41(1):325. PubMed ID: 36397155
[TBL] [Abstract][Full Text] [Related]
25. Melanoma MicroRNA signature predicts post-recurrence survival.
Segura MF; Belitskaya-Lévy I; Rose AE; Zakrzewski J; Gaziel A; Hanniford D; Darvishian F; Berman RS; Shapiro RL; Pavlick AC; Osman I; Hernando E
Clin Cancer Res; 2010 Mar; 16(5):1577-86. PubMed ID: 20179230
[TBL] [Abstract][Full Text] [Related]
26. Age favoured overall survival in a large population-based Danish patient cohort treated with anti-PD1 immune checkpoint inhibitor for metastatic melanoma.
Bastholt L; Schmidt H; Bjerregaard JK; Herrstedt J; Svane IM
Eur J Cancer; 2019 Sep; 119():122-131. PubMed ID: 31442816
[TBL] [Abstract][Full Text] [Related]
27. A four-miRNA signature identified from genome-wide serum miRNA profiling predicts survival in patients with nasopharyngeal carcinoma.
Liu N; Cui RX; Sun Y; Guo R; Mao YP; Tang LL; Jiang W; Liu X; Cheng YK; He QM; Cho WC; Liu LZ; Li L; Ma J
Int J Cancer; 2014 Mar; 134(6):1359-68. PubMed ID: 23999999
[TBL] [Abstract][Full Text] [Related]
28. Association Between Sex and Immune Checkpoint Inhibitor Outcomes for Patients With Melanoma.
Jang SR; Nikita N; Banks J; Keith SW; Johnson JM; Wilson M; Lu-Yao G
JAMA Netw Open; 2021 Dec; 4(12):e2136823. PubMed ID: 34854905
[TBL] [Abstract][Full Text] [Related]
29. Correlation of plasma exosomal microRNAs with the efficacy of immunotherapy in
Peng XX; Yu R; Wu X; Wu SY; Pi C; Chen ZH; Zhang XC; Gao CY; Shao YW; Liu L; Wu YL; Zhou Q
J Immunother Cancer; 2020 Jan; 8(1):. PubMed ID: 31959728
[TBL] [Abstract][Full Text] [Related]
30. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
31. miRNAs as Key Players in the Management of Cutaneous Melanoma.
Lorusso C; De Summa S; Pinto R; Danza K; Tommasi S
Cells; 2020 Feb; 9(2):. PubMed ID: 32054078
[TBL] [Abstract][Full Text] [Related]
32. Comprehensive upstream and downstream regulatory analyses identify miR-675-3p as a potential prognostic biomarker in melanoma.
Zhao CC; Guo H; Wang Y; Li JH
Hum Cell; 2021 Mar; 34(2):654-666. PubMed ID: 33400243
[TBL] [Abstract][Full Text] [Related]
33. Neoadjuvant Immunotherapy for Locally Advanced Melanoma.
Pelster MS; Amaria RN
Curr Treat Options Oncol; 2020 Feb; 21(2):10. PubMed ID: 32025932
[TBL] [Abstract][Full Text] [Related]
34. A Panel of MicroRNA Signature as a Tool for Predicting Survival of Patients with Urothelial Carcinoma of the Bladder.
Inamoto T; Uehara H; Akao Y; Ibuki N; Komura K; Takahara K; Takai T; Uchimoto T; Saito K; Tanda N; Yoshikawa Y; Minami K; Hirano H; Nomi H; Kato R; Hayashi T; Azuma H
Dis Markers; 2018; 2018():5468672. PubMed ID: 30026881
[TBL] [Abstract][Full Text] [Related]
35. A 4-microRNA signature predicts lymph node metastasis and prognosis in breast cancer.
Chen X; Wang YW; Zhu WJ; Li Y; Liu L; Yin G; Gao P
Hum Pathol; 2018 Jun; 76():122-132. PubMed ID: 29555574
[TBL] [Abstract][Full Text] [Related]
36. Upregulation of MicroRNA-1246 Is Associated with BRAF Inhibitor Resistance in Melanoma Cells with Mutant BRAF.
Kim JH; Ahn JH; Lee M
Cancer Res Treat; 2017 Oct; 49(4):947-959. PubMed ID: 28052651
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of tumor microenvironment and biomarkers of immune checkpoint inhibitor response in metastatic renal cell carcinoma.
Brown LC; Zhu J; Desai K; Kinsey E; Kao C; Lee YH; Pabla S; Labriola MK; Tran J; Dragnev KH; Tafe LJ; Dayyani F; Gupta RT; McCall S; George DJ; Glenn ST; Nesline MK; George S; Zibelman M; Morrison C; Ornstein MC; Zhang T
J Immunother Cancer; 2022 Oct; 10(10):. PubMed ID: 36252996
[TBL] [Abstract][Full Text] [Related]
38. A microRNA signature associated with early recurrence in breast cancer.
Pérez-Rivas LG; Jerez JM; Carmona R; de Luque V; Vicioso L; Claros MG; Viguera E; Pajares B; Sánchez A; Ribelles N; Alba E; Lozano J
PLoS One; 2014; 9(3):e91884. PubMed ID: 24632820
[TBL] [Abstract][Full Text] [Related]
39. Autoantibodies May Predict Immune-Related Toxicity: Results from a Phase I Study of Intralesional
Da Gama Duarte J; Parakh S; Andrews MC; Woods K; Pasam A; Tutuka C; Ostrouska S; Blackburn JM; Behren A; Cebon J
Front Immunol; 2018; 9():411. PubMed ID: 29552014
[TBL] [Abstract][Full Text] [Related]
40. Identification of a nine-miRNA signature for the prognosis of Uveal Melanoma.
Xin X; Zhang Y; Ling F; Wang L; Sheng X; Qin L; Zhao X
Exp Eye Res; 2019 Mar; 180():242-249. PubMed ID: 30615885
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
